Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InMode Ltd. stock logo
INMD
InMode
$13.36
-4.9%
$14.66
$13.28
$19.85
$844.47M1.981.19 million shs2.37 million shs
Envista Holdings Co. stock logo
NVST
Envista
$18.44
-2.3%
$17.09
$14.22
$23.00
$3.20B0.992.57 million shs1.66 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$79.15
-1.3%
$73.64
$36.93
$81.54
$3.99B-2.69770,288 shs621,294 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$142.88
-0.1%
$108.75
$55.00
$177.37
$4.84B2.11.36 million shs455,068 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
InMode Ltd. stock logo
INMD
InMode
0.00%-5.65%-9.18%-27.03%-27.11%
Envista Holdings Co. stock logo
NVST
Envista
0.00%-1.76%+1.93%+10.91%+1.49%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+4.82%+5.43%+60.42%+71.47%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%+2.75%+17.30%+108.49%+0.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
InMode Ltd. stock logo
INMD
InMode
3.6688 of 5 stars
4.13.00.00.02.31.71.9
Envista Holdings Co. stock logo
NVST
Envista
3.3919 of 5 stars
2.22.00.03.82.70.01.9
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.7465 of 5 stars
4.63.00.04.62.92.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.2854 of 5 stars
1.42.00.00.01.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InMode Ltd. stock logo
INMD
InMode
2.13
Hold$18.5438.78% Upside
Envista Holdings Co. stock logo
NVST
Envista
2.33
Hold$20.239.71% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.11
Buy$106.7834.91% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.80
Moderate Buy$125.11-12.44% Downside

Current Analyst Ratings Breakdown

Latest INMD, TMDX, SLNO, and NVST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.00
6/3/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/27/2025
Envista Holdings Co. stock logo
NVST
Envista
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/27/2025
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$21.00 ➝ $23.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00
5/5/2025
Envista Holdings Co. stock logo
NVST
Envista
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $18.00
5/2/2025
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$21.00
4/30/2025
InMode Ltd. stock logo
INMD
InMode
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $24.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InMode Ltd. stock logo
INMD
InMode
$392.41M2.15$1.28 per share10.40$10.12 per share1.32
Envista Holdings Co. stock logo
NVST
Envista
$2.50B1.25$1.43 per share12.91$17.04 per share1.08
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$488.23M9.90$0.27 per share530.08$4.20 per share34.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InMode Ltd. stock logo
INMD
InMode
$181.27M$2.335.697.34N/A45.91%18.25%16.33%7/30/2025 (Estimated)
Envista Holdings Co. stock logo
NVST
Envista
-$1.12B-$6.53N/A15.241.27-44.56%3.86%2.21%8/6/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$4.62N/AN/AN/AN/A-61.99%-55.21%8/6/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M$1.36152.0099.92N/A8.14%18.74%4.39%7/30/2025 (Estimated)

Latest INMD, TMDX, SLNO, and NVST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
5/1/2025Q1 2025
Envista Holdings Co. stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
4/28/2025Q1 2025
InMode Ltd. stock logo
INMD
InMode
$0.45$0.31-$0.14$0.26$82.21 million$77.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
InMode Ltd. stock logo
INMD
InMode
N/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InMode Ltd. stock logo
INMD
InMode
N/A
10.23
9.38
Envista Holdings Co. stock logo
NVST
Envista
0.44
2.04
1.76
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
17.26
17.26
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.42
8.20
7.33

Institutional Ownership

CompanyInstitutional Ownership
InMode Ltd. stock logo
INMD
InMode
68.04%
Envista Holdings Co. stock logo
NVST
Envista
N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
InMode Ltd. stock logo
INMD
InMode
6.92%
Envista Holdings Co. stock logo
NVST
Envista
1.30%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
InMode Ltd. stock logo
INMD
InMode
48063.21 million64.75 millionOptionable
Envista Holdings Co. stock logo
NVST
Envista
12,700169.49 million169.95 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million37.81 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.21 millionOptionable

Recent News About These Companies

Price Over Earnings Overview: TransMedics Group
These 24 Stocks Are Ripe for a Short Squeeze
TransMedics Group, Inc. (TMDX): A Bull Case Theory
TransMedics Group, Inc. (TMDX): A Bull Case Theory

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
InMode stock logo

InMode NASDAQ:INMD

$13.36 -0.69 (-4.91%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$13.43 +0.07 (+0.52%)
As of 06/13/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Envista stock logo

Envista NYSE:NVST

$18.44 -0.43 (-2.28%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$18.43 -0.01 (-0.03%)
As of 06/13/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$79.15 -1.05 (-1.31%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$79.17 +0.02 (+0.02%)
As of 06/13/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$142.88 -0.16 (-0.11%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$143.47 +0.59 (+0.41%)
As of 06/13/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.